

---

## LIST OF PROFILES

---

### OPENING SESSION



Photo by Mr. Tetsuo Sakuma

#### **Kiyoshi KUROKAWA**

Kiyoshi Kurokawa is well known both nationally and internationally in the medical community and more recently in the science policy community through his leadership as president of the Science Council of Japan. Because of his highly unique and unusual professional career, which spans over 15 years each in Japan and the United States, he has been recognized as a leader and an advocate for many academic and professional activities as well as various reform policies in Japan and world affairs. Dr. Kurokawa has served as special advisor to the prime minister's cabinet (2006–2008) and is a professor at the National Graduate Institute for Policy Studies, commissioner of the WHO Commission for Social Determinants of Health, chair of the Health Policy Institute in Japan, founding governor of the Japan Chapter of the American College of Physicians, and professor emeritus of the University of Tokyo.



#### **Keizo TAKEMI**

Keizo Takemi is a senior fellow at the Japan Center for International Exchange (JCIE), a fellow at the Sasakawa Memorial Health Foundation, and a professor of political science and economics at Tokai University. He was a research fellow at the Harvard School of Public Health from November 2007 to June 2009. Professor Takemi was a member of the House of Councillors (Liberal Democratic Party) in the Japanese Diet for 12 years until August 2007 and served in the Abe cabinet as senior vice minister for health, labour, and welfare. He led the initiative to establish the UN Trust Fund for Human Security when he was state secretary for foreign affairs in 1999 and was subsequently named by then UN Secretary-General Kofi Annan to serve as a member of the High Level Panel on UN System-Wide Coherence in Areas of Development, Humanitarian Assistance and Environment. Since September 2007, he has been serving as the chair of a policymaking platform for public and private partnership on global health, known as the study group on “Challenges in Global Health and Japan’s Contributions” before it was restructured as the executive committee of JCIE’s program on Global Health and Human Security in August 2009.

#### **[Moderator]**



#### **Tadashi YAMAMOTO**

Tadashi Yamamoto is president of the Japan Center for International Exchange (JCIE), which he founded in 1970. He is a member of the Trilateral Commission, Japan-UK 21st Century Group, Japan-German Forum, and the Japan-Korea Forum. Since 2004, JCIE has been involved with various initiatives related to global health issues and is the secretariat for the Friends of the Global Fund, Japan (FGFJ), of which Mr. Yamamoto is director. He also helped create a working group on Challenges in Global Health and Japan’s Contributions, which is exploring ways of building partnerships among various actors around the world in the field of global health. He has received the Commander’s Cross of the Order of Merit from the German government, Honorable Commander of the Most Excellent Order of the British Empire, and Honorary Officer (AO) from the Australian government. After studying at Sophia University in Japan, he received a BA from St. Norbert’s College and an MBA from Marquette University, both in the United States.

## SESSION 1



### **Stefan EMBLAD**

Stefan Emlad, a Swedish national, joined the Global Fund to Fight AIDS, Tuberculosis and Malaria in May 2009 as director for resource mobilization. He worked for a number of years for the Swedish Government in the Ministries of Finance and Foreign Affairs focused on international financial cooperation and debt issues. He held various positions of responsibility including director in the Department for Multilateral Development and alternate governor to the African, Asian, and Inter-American Development Banks. He represented Sweden at replenishments of the World Bank concessional finance window (IDA). Stefan has also worked for the United Nations Development Programme in Cambodia, the European Commission, and most recently the World Bank. As advisor to the vice president of concessional finance and global partnerships, he was deeply involved in the IDA15 replenishment and worked on the bank's trust fund portfolio and innovative financing mechanisms. He holds an MSc in International Economics and an MBA, both from the Stockholm School of Economics.

### **The Global Fund to Fight AIDS, Tuberculosis and Malaria (The Global Fund)**

The Global Fund is a unique global public-private partnership dedicated to attracting and disbursing additional resources to prevent and treat HIV/AIDS, tuberculosis, and malaria. This partnership among governments, civil society, the private sector, and affected communities represents a new approach to international health financing. The Global Fund works in close collaboration with other bilateral and multilateral organizations to supplement existing efforts dealing with the three diseases.

Since its creation in 2002, the Global Fund has become the dominant financier of programs to fight AIDS, tuberculosis, and malaria, with approved funding of US\$19.4 billion for more than 600 programs in 145 countries. To date, programs supported by the Global Fund have saved 5.7 million lives by providing AIDS treatment for 2.8 million people, anti-tuberculosis treatment for 7 million people, and the distribution of 122 million insecticide-treated nets for the prevention of malaria.



### **Joelle TANGUY**

Joelle Tanguy joined Global Alliance for Vaccines and Immunisation (GAVI) in July 2009 and brings a solid track record in global health advocacy, resource mobilization, public affairs, and organizational development. She has spent the last 20 years in senior management of global health organisations, most recently as senior vice president at the Global Business Coalition on HIV/AIDS, TB and Malaria (GBC), as well as committee member and focal point for the private sector on the Board of Directors of the Global Fund to Fight AIDS, Tuberculosis and Malaria. Her previous responsibilities included director of advocacy and public affairs at the Global Alliance for TB Drug Development and US executive director of Médecins Sans Frontières (MSF). She also brings experience from Africa, where she headed medical missions in Uganda, the Democratic Republic of Congo, and Somalia. Joelle is a French national and holds an MBA from HEC/ISA, France's top business school and an MA from Stanford University.

### **GAVI Alliance**

The GAVI Alliance is a unique partnership of public- and private-sector actors with a single, shared focus: to improve child health in the poorest countries by extending the reach and quality of immunization coverage within strengthened health services. GAVI's partners include UNICEF, the WHO, the World Bank, civil society organisations, public health institutions, donor and implementing country governments, the Bill & Melinda Gates Foundation, other private

philanthropists, vaccine industry representatives, IFFIm, the financial community, and others whose collective efforts and expertise are enabling much greater progress to be made in this field than ever before.



### **Michael MADNICK**

Michael Madnick joined the Global Alliance for Improved Nutrition (GAIN) in March 2010 as deputy executive director. In this role, he works with GAIN's executive director and the leadership team to define and implement the foundation's strategic goals. Michael comes to GAIN from the Bill & Melinda Gates Foundation, where he served as deputy director of global health policy and advocacy. In this capacity, he oversaw several teams, including Advocacy, Government Relations, Multilateral Relations, Industry Relations, International Financial Partnerships, and Emerging Donors. From 2000 to 2007 he served as vice president for partnership and later as senior vice president of the United Nations Foundation (UNF), where he institutionalized an organization-wide partnership strategy. This strategy transitioned UNF from a private foundation-like model toward a cross-sector partnership facility able to work on a far larger scale of impact. He also led the UNF-Gates relationship for several years, which resulted in numerous collaborations. Michael serves on various boards and advocacy- and partnership-related sub-committees. He holds a JD from Pace University School of Law and a BA in political science from the State University of New York—Albany.

### **The Global Alliance for Improved Nutrition (GAIN)**

The Global Alliance for Improved Nutrition (GAIN) is an alliance driven by the vision of a world without malnutrition. GAIN was created in 2002 at a Special Session of the UN General Assembly on Children. GAIN is a Swiss foundation that mobilizes public-private partnerships and provides financial and technical support to deliver foods to those people most at risk of malnutrition. GAIN's innovative partnerships in more than 25 countries are reaching an estimated 273 million individuals, half of whom are women and children. Its portfolio is growing and its target is to reach one billion people with innovative nutritious foods. GAIN is headquartered in Geneva, Switzerland. Regional offices in Cairo, Johannesburg, New Delhi, and Washington DC support its programs.



### **Jean-Pierre PACCAUD**

Jean-Pierre Paccaud has been part of the executive team at the Drugs for Neglected Diseases Initiative (DNDi) since 2007. He is responsible for the business development activities of the foundation, including opportunity identification, contract structure and negotiations, IP, and alliance management. Prior to joining DNDi, he served as head of business development for R&D products at OM Pharma. In 2003, he founded and led Athelas SA, a startup company active in the field of anti-bacterial drug discovery, until its merger with Merlion Pharmaceuticals in 2006. Before taking on entrepreneurial challenges in industry, Dr. Paccaud spent more than 18 years in academia, working in immunology, diabetes, and cell biology, and was tenured at the University of Geneva School of Medicine. He is the author of more than 40 peer-reviewed articles. Trained as a molecular and cellular biologist, Dr. Paccaud completed his post-doctoral studies at the University of California at Berkeley and earned his PhD at the University of Geneva School of Medicine. Since 2001, he has also been consulting for Swiss biotech investment funds.

### **The Drugs for Neglected Diseases initiative (DNDi)**

DNDi is a not-for-profit product development partnership working to research and develop new and improved treatments for neglected diseases, in particular human African trypanosomiasis (sleeping sickness), leishmaniasis, Chagas disease, and malaria. With the objective of addressing unmet patient needs for these diseases,

DNDi was established in 2003 by the Oswaldo Cruz Foundation from Brazil, the Indian Council for Medical Research, the Kenya Medical Research Institute, the Ministry of Health of Malaysia, the Pasteur Institute, and Médecins sans Frontières. WHO/TDR acts as a permanent observer. Working in partnership with industry and academia, DNDi has the largest ever R&D portfolio for kinetoplastid diseases. Since 2007, DNDi has delivered three products: two fixed-dose anti-malarials, “ASAQ” and “ASMQ,” and a combination treatment for the advanced stage of sleeping sickness, “NECT” (nifurtimox-eflornithine combination therapy).

The first Chagas treatment for children, pediatric strength benznidazole, will be made available as a public good in the near future by DNDi and Pharmaceutical Laboratory of Pernambuco (LAFEPE) in Brazil. Furthermore, in 2009 DNDi signed a collaboration and license agreement with the Japanese pharmaceutical company Eisai Co. Ltd. for the clinical development of the promising compound E1224 to treat Chagas disease.

## SESSION 2

[Moderator]



### **Akira KOJIMA**

Akira Kojima is a senior research fellow at the Japan Center for Economic Research (JCER), an independent public policy research institute established in 1963. After graduating from Waseda University, he entered NIKKEI in 1965 and studied at the Graduate School of Manchester University as a British Council Scholar in 1969–1970. He was a special correspondent in NIKKEI’s New York Bureau (1978–1982) and became a senior writer and editorialist in 1982. In 1992, he was assigned to be a deputy managing editor and international news editor. In 1997, he became the director and chief editorialist, and in 2000, he was assigned as a managing director and chief editorialist at NIKKEI. From 2004 to 2007, he served as chairman of the JCER and since 2008 as a trustee and senior fellow of the JCER. Mr. Kojima is also a member of Trilateral Commission and the Aspen Institute Japan and a visiting professor at the National Graduate Institute for Policy Studies. He is also a vice president of the National Institute for Research Advancement, a visiting professor at Waseda University Institute of Asia-Pacific Studies, a Fujita Chair Professor of Keio University, and an advisor to the Judicial System Reform Promotion Head Office. In 1988, Mr. Kojima was awarded the Vaughn-Ueda International Journalist award. He is the author of numerous books, including “Nihon no Sentaku: Tekisha no moderu e” [Choices for Japan: toward a survival of the fittest model].



### **Toshio ARIMA**

Toshio Arima is an executive corporate advisor at Fuji Xerox, which he joined in 1967. He became the company’s director in 1992 and the managing director in 1996, and he was appointed president and CEO of Xerox International Partners that same year. In 2002, he was made president of Fuji Xerox and became board director and executive advisor in 2007. He has held his current position as executive corporate advisor since June 2008. In addition to his position with Fuji Xerox, he is a board member of the United Nations Global Compact and chairman of the Global Compact Board Japan.



### **Tatsuo MIZUNO**

Tatsuo Mizuno is the general manager of Sumitomo Chemical’s Vector Control Division, where he is in charge of research and development, production, and sales of products aimed at controlling malaria and other infectious diseases. He also served previously as the general manager of the Vector Control Department in the Environmental Health Division. Before joining Sumitomo Chemical, he served as managing director for finance and administration at Rainbow Chemical. Mr. Mizuno has a BA from the Agricultural Department of Hokkaido University.



### **Hiroshi OHTSUKI**

Hiroshi Ohtsuki is a corporate officer in the Corporate Communications Department at Takeda Pharmaceutical. Receiving a doctorate degree in pharmacology in 1985 from Kyoto Pharmaceutical University, Mr. Ohtsuki joined Takeda and worked on research on basic cardiology at the company's R&D center, as well as in the Marketing Division starting in 1988. In 1990, Mr. Ohtsuki resigned from Takeda and entered Amato Pharmaceutical Products, where he was appointed president in 1997. Returning to Takeda in 2003, he was appointed corporate officer and president of the healthcare company. He assumed his present position as corporate officer in charge of the Corporate Communications Department in 2009. He has also been a member of Keizai Doyukai (Japan Association of Corporate Executives) since 2008.



### **Satoru YAMAMOTO**

Satoru Yamamoto is a deputy general manager and head of the Planning Section of the Product Planning Department at Daiwa Securities, a leading retail securities house in Japan. He currently leads Daiwa's "Social Impact Investment" initiatives, including IFFIm Vaccine Bonds (launched in March 2008, February 2009, and March 2010), World Bank World CO2LTM Bond (June 2008), IFC Microfinance Bonds (November 2009), World Bank Green Bond (January 2010), ADB Water Bonds (April 2010), EIB Climate Awareness Bonds (May 2010), EBRD Microfinance Bonds (June 2010), IDB Poverty Reduction Bonds (July 2010), and AfDB Education Bonds (to be issued in August 2010). The IFC Microfinance Bonds were the very first microfinance investment products in Japan and raised the equivalent of US\$300 million, an amount comparable to IFC's annual microfinance program in recent years. Mr. Yamamoto has been engaged in product planning and development for retail investors since 2001. Prior to that, he was responsible for sales planning at Daiwa's headquarters. He holds an MBA from the Haas School of Business at the University of California, Berkeley (USA), and a BA in economics from Keio University (Japan).



### **Satoshi KITAMURA**

Satoshi Kitamura joined Ajinomoto in 1995 as a product manager for the Food Product Division of the Food Department. Since 2005, he has taken on the role of corporate citizenship manager for the CSR Department. He has been taking the initiative to promote nutrition improvement, protection of food resources, and social business development in cooperation with various sectors in developing countries.



### **Kenji TODA**

Kenji Toda has been senior vice president of government relations at the Japanese pharmaceutical company Eisai since 2006. Mr. Toda has played a senior role at the Japan Pharmaceutical Manufacturers Association (JPMA) as chairman, international affairs, where under his leadership the association committed itself to capacity-building activities to support developing countries in Asia. He has also served as deputy director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) since 2009. Mr. Toda is a Japanese national and graduated in applied microbiology and bio-engineering from Kyushu University in 1969. He joined Eisai upon graduation and has held a number of positions within the company, including president of Eisai Europe, based in London between 1988 and 1997. He is an honorary fellow of University College London and on July 1, 2010 was made an Officer of the Order of the British Empire (OBE).